Corporate

Raj Oil Mills ends at marginal discount on debut

Raj Oil Mills finally settled at Rs 118 on the BSE today. The debutant touched an intra-day high of Rs 133, up 6.5% from its opening. The counter clocked a volume of over 17.3 million shares on the first day. ____________________________________________________________ F&O OUTLOOK: Downside limited from current levels US markets end in the green Raj Oil Mills made its debut on the BSE today at Rs 125, at a premium of 7% or Rs 9.15 to its issue price of Rs 120 per share. The stock is now trading at Rs 119 The stock soon touched a high of Rs 133 after opening at the exchange. As the trading progressed, the scrip fell to a low of Rs 115. The counter witnessed trades of over 12 million shares so far. The initial public offer(IPO), which opened on July 20, was fully subscribed on the final day of the offer. The IPO received bids for over 98.16 lakh equity shares against the offer size of 95 lakh shares. It also got a positive response from non-institutional investors, as it was subscribed nearly 1.5 times by them. The company reported a net profit of Rs 29.62 crore on sales of Rs 317.76 crore in the year ended December 2008.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
Corps to ignore Bollywood in favour of Hollywood: study
The Indian entertainment and media (E&M) corporates will prefer Hollywood over Bollywood in terms of investment in the near future, as over 90 per cent of the Bollywood movies flop annually, a study said.
Popular Articles
payday loans online

Forex reserves up at $286.376 billion
India"s foreign exchange reserves rose by $0.962 million to $286.376 billion for the week ended November 13 from $285.414 billion in the previous week, the Reserve Bank of India (RBI) said today.

Top drug firms take in-licensing route to up sales
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy’s Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales. They introduce the in-licensed drugs — which are mostly in the premium skin care segment — on payment of an upfront fee to the brand owners, who also get a share of the sales revenue.